-
Optimized Treatment Schedules for Chronic Myeloid Leukemia
Authors:
Qie He,
Junfeng Zhu,
David Dingli,
Jasmine Foo,
Kevin Leder
Abstract:
Over the past decade, several targeted therapies (e.g. imatinib, dasatinib, nilotinib) have been developed to treat Chronic Myeloid Leukemia (CML). Despite an initial response to therapy, drug resistance remains a problem for some CML patients. Recent studies have shown that resistance mutations that preexist treatment can be detected in a substan- tial number of patients, and that this may be ass…
▽ More
Over the past decade, several targeted therapies (e.g. imatinib, dasatinib, nilotinib) have been developed to treat Chronic Myeloid Leukemia (CML). Despite an initial response to therapy, drug resistance remains a problem for some CML patients. Recent studies have shown that resistance mutations that preexist treatment can be detected in a substan- tial number of patients, and that this may be associated with eventual treatment failure. One proposed method to extend treatment efficacy is to use a combination of multiple targeted therapies. However, the design of such combination therapies (timing, sequence, etc.) remains an open challenge. In this work we mathematically model the dynamics of CML response to combination therapy and analyze the impact of combination treatment schedules on treatment efficacy in patients with preexisting resistance. We then propose an optimization problem to find the best schedule of multiple therapies based on the evolution of CML according to our ordinary differential equation model. This resulting optimiza- tion problem is nontrivial due to the presence of ordinary different equation constraints and integer variables. Our model also incorporates realistic drug toxicity constraints by tracking the dynamics of patient neutrophil counts in response to therapy. Using realis- tic parameter estimates, we determine optimal combination strategies that maximize time until treatment failure.
△ Less
Submitted 17 April, 2016;
originally announced April 2016.
-
A deterministic model for the occurrence and dynamics of multiple mutations in hierarchically organized tissues
Authors:
B. Werner,
D. Dingli,
A. Traulsen
Abstract:
We model a general, hierarchically organized tissue by a multi compartment approach, allowing any number of mutations within a cell. We derive closed solutions for the deterministic clonal dynamics and the reproductive capacity of single clones. Our results hold for the average dynamics in a hierarchical tissue characterized by an arbitrary combination of proliferation parameters.
We model a general, hierarchically organized tissue by a multi compartment approach, allowing any number of mutations within a cell. We derive closed solutions for the deterministic clonal dynamics and the reproductive capacity of single clones. Our results hold for the average dynamics in a hierarchical tissue characterized by an arbitrary combination of proliferation parameters.
△ Less
Submitted 14 May, 2013;
originally announced May 2013.
-
Genetic progression and the waiting time to cancer
Authors:
Niko Beerenwinkel,
Tibor Antal,
David Dingli,
Arne Traulsen,
Kenneth W. Kinzler,
Victor E. Velculescu,
Bert Vogelstein,
Martin A. Nowak
Abstract:
Cancer results from genetic alterations that disturb the normal cooperative behavior of cells. Recent high-throughput genomic studies of cancer cells have shown that the mutational landscape of cancer is complex and that individual cancers may evolve through mutations in as many as 20 different cancer-associated genes. We use data published by Sjoblom et al. (2006) to develop a new mathematical…
▽ More
Cancer results from genetic alterations that disturb the normal cooperative behavior of cells. Recent high-throughput genomic studies of cancer cells have shown that the mutational landscape of cancer is complex and that individual cancers may evolve through mutations in as many as 20 different cancer-associated genes. We use data published by Sjoblom et al. (2006) to develop a new mathematical model for the somatic evolution of colorectal cancers. We employ the Wright-Fisher process for exploring the basic parameters of this evolutionary process and derive an analytical approximation for the expected waiting time to the cancer phenotype. Our results highlight the relative importance of selection over both the size of the cell population at risk and the mutation rate. The model predicts that the observed genetic diversity of cancer genomes can arise under a normal mutation rate if the average selective advantage per mutation is on the order of 1%. Increased mutation rates due to genetic instability would allow even smaller selective advantages during tumorigenesis. The complexity of cancer progression thus can be understood as the result of multiple sequential mutations, each of which has a relatively small but positive effect on net cell growth.
△ Less
Submitted 25 July, 2007;
originally announced July 2007.